Spyre Therapeutics, Inc.
SYRE
$16.67
$0.784.91%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -100.00% |
| Cost of Revenue | 61.31% | 99.25% | 135.49% | 440.94% | 278.98% |
| Gross Profit | -61.31% | -100.40% | -137.64% | -462.08% | -290.99% |
| SG&A Expenses | -3.96% | 6.66% | 32.87% | 92.76% | 97.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.47% | 45.56% | 76.01% | 116.56% | 128.25% |
| Operating Income | -28.47% | -46.24% | -77.33% | -119.13% | -132.01% |
| Income Before Tax | -11.22% | 42.63% | 38.62% | 27.03% | 31.83% |
| Income Tax Expenses | -88.57% | -90.48% | 296.15% | 316.67% | 117.50% |
| Earnings from Continuing Operations | -11.20% | 42.64% | 38.60% | 27.01% | 31.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.20% | 42.64% | 38.60% | 27.01% | 31.76% |
| EBIT | -28.47% | -46.24% | -77.33% | -119.13% | -132.01% |
| EBITDA | 32.61% | -9.72% | -77.83% | -121.31% | -136.36% |
| EPS Basic | -360.20% | 95.47% | 95.57% | 111.73% | 101.29% |
| Normalized Basic EPS | 79.55% | 89.53% | 89.36% | 82.13% | 44.83% |
| EPS Diluted | -360.20% | 95.47% | 95.57% | 111.73% | 101.29% |
| Normalized Diluted EPS | 79.55% | 89.53% | 89.36% | 82.13% | 44.83% |
| Average Basic Shares Outstanding | 122.89% | 251.50% | 583.68% | 844.58% | 570.30% |
| Average Diluted Shares Outstanding | 122.89% | 251.50% | 583.68% | 844.58% | 570.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |